Curanex Pharmaceuticals Inc Common Stock (CURX) - Total Liabilities
Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has total liabilities worth $185.96K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Curanex Pharmaceuticals Inc Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Curanex Pharmaceuticals Inc Common Stock - Total Liabilities Trend (2022–2024)
This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CURX total asset value.
Curanex Pharmaceuticals Inc Common Stock Competitors by Total Liabilities
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
Germany | €1.15 Billion |
|
Magontec Ltd
AU:MGL
|
Australia | AU$26.01 Million |
|
Solo Brands, Inc.
NYSE:SBDS
|
USA | $316.38 Million |
|
GACM Technologies Limited
NSE:GATECH
|
India | Rs166.67 Million |
|
Together Startup Network Ltd
TA:TGTR
|
Israel | ILA56.03 Million |
|
ECP Emerging Growth Ltd
AU:ECP
|
Australia | AU$10.43 Million |
|
Daesang Holdings Co Ltd Pref
KO:084695
|
Korea | ₩3.03 Trillion |
|
Aprea Therapeutics Inc
NASDAQ:APRE
|
USA | $5.30 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Curanex Pharmaceuticals Inc Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CURX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 77.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curanex Pharmaceuticals Inc Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual total liabilities of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.57K | +2.09% |
| 2023-12-31 | $14.28K | -- |
| 2022-12-31 | $0.00 | -- |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more